What is it about?
A systematic review and meta-analysis of the efficacy of levofloxacin triple therapy in the first-line and second-line therapy for H. pylori infection.
Featured Image
Why is it important?
We found that the efficacy of levofloxacin triple therapy has been lower than 80% in many countries and it is not recommended when the levofloxacin resistance is higher than 5-10%.
Perspectives
Further trials are warranted to assess the efficacy of levofloxacin sequential therapy or levofloxacin concomitant therapy or addition of bismuth to the levofloxacin triple therapy in the second-line treatment for H. pylori infection.
Jyh-Ming Liou
Read the Original
This page is a summary of: Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments ofHelicobacter pyloriinfection, Alimentary Pharmacology & Therapeutics, June 2016, Wiley,
DOI: 10.1111/apt.13712.
You can read the full text:
Contributors
The following have contributed to this page
